Current Report Filing (8-k)
October 24 2016 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 24, 2016
INOVIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-14888
|
|
33-0969592
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
660 W. Germantown Pike, Suite 110
Plymouth Meeting, Pennsylvania
|
|
19462
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(267) 440-4200
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01
.
|
Other Events
.
|
On October 24, 2016, we issued a press release to announce that
the U.S. Food and Drug Administration (FDA) has placed a clinical hold on our proposed phase III clinical program for VGX-3100. The press release is attached to this Form 8-K, and the text of the press release is incorporated by reference into
this Form 8-K as though fully set forth herein.
Item 9.01
.
|
Financial Statements and Exhibits
.
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press release dated October 24, 2016
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
INOVIO PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Peter Kies
|
|
|
Peter Kies,
|
|
|
Chief Financial Officer
|
Date: October 24, 2016
-3-
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2024 to May 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From May 2023 to May 2024